176 related articles for article (PubMed ID: 30734299)
21. MHC II on transfused murine blood is not required for alloimmunization against MHC I.
Gilson CR; Cadwell CM; Smith NH; Hendrickson JE; Zimring JC
Vox Sang; 2010 Nov; 99(4):369-74. PubMed ID: 20546207
[TBL] [Abstract][Full Text] [Related]
22. A novel tool for B-cell tolerance research: characterization of mouse alloantibody development using a simple and reliable cellular ELISA technique.
Fan X; Tyerman K; Ang A; Koo K; Parameswaran K; Tao K; Mai L; Lang H; West LJ
Transplant Proc; 2005; 37(1):29-31. PubMed ID: 15808536
[TBL] [Abstract][Full Text] [Related]
23. Effects of leukocyte depletion and UVB irradiation on alloantigenicity of major histocompatibility complex antigens in platelet concentrates: a comparative study.
Kao KJ
Blood; 1992 Dec; 80(11):2931-7. PubMed ID: 1450418
[TBL] [Abstract][Full Text] [Related]
24. Ultraviolet B irradiation in the prevention of alloimmunization in a dog platelet transfusion model.
Slichter SJ; Abrams K; Gettinger I; Christoffel T; Gaur L; Latchman Y; Nelson K; Pellham E; Bailey SL; Bolgiano D
Transfusion; 2016 Jun; 56(6):1340-7. PubMed ID: 27184061
[TBL] [Abstract][Full Text] [Related]
25. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients.
Hogge DE; McConnell M; Jacobson C; Sutherland HJ; Benny WB; Massing BG
Transfusion; 1995 Aug; 35(8):645-52. PubMed ID: 7631404
[TBL] [Abstract][Full Text] [Related]
26. Marginal zone B cells are responsible for the production of alloantibodies following platelet transfusion in mice.
Couvidou A; Angénieux C; Ruch L; Mangin PH; Gachet C; Maître B
Blood Adv; 2023 Apr; 7(8):1356-1365. PubMed ID: 36490266
[TBL] [Abstract][Full Text] [Related]
27. Pathogen-reduced platelets for the prevention of bleeding.
Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
[TBL] [Abstract][Full Text] [Related]
28. In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody.
Morrell CN; Murata K; Swaim AM; Mason E; Martin TV; Thompson LE; Ballard M; Fox-Talbot K; Wasowska B; Baldwin WM
Circ Res; 2008 Apr; 102(7):777-85. PubMed ID: 18296616
[TBL] [Abstract][Full Text] [Related]
29. Induction of immune tolerance across major histocompatibility complex barrier by transfusion of ultraviolet B-irradiated immature dendritic cells.
Xia CQ; Kao KJ
Transfusion; 2005 Feb; 45(2):181-8. PubMed ID: 15660825
[TBL] [Abstract][Full Text] [Related]
30. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
[TBL] [Abstract][Full Text] [Related]
31. Immune responsiveness against allogeneic platelet transfusions is determined by the recipient's major histocompatibility complex class II phenotype.
Sayeh E; Aslam R; Speck ER; Le-Tien H; Lazarus AH; Freedman J; Semple JW
Transfusion; 2004 Nov; 44(11):1572-8. PubMed ID: 15504162
[TBL] [Abstract][Full Text] [Related]
32. The challenge of platelet alloimmunization: management and prevention.
Kickler TS
Transfus Med Rev; 1990 Oct; 4(4 Suppl 1):8-18. PubMed ID: 2134640
[TBL] [Abstract][Full Text] [Related]
33. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions.
Trial to Reduce Alloimmunization to Platelets Study Group
N Engl J Med; 1997 Dec; 337(26):1861-9. PubMed ID: 9417523
[TBL] [Abstract][Full Text] [Related]
34. IgM and IgG alloantibody responses to MHC class I and II following rat renal allograft rejection. Effects of transplantectomy and posttransplantation blood transfusion.
Wray DW; Baldwin WM; Sanfilippo F
Transplantation; 1992 Jan; 53(1):167-74. PubMed ID: 1370736
[TBL] [Abstract][Full Text] [Related]
35. Alloimmunization to transfused platelets requires priming of CD4+ T cells in the splenic microenvironment in a murine model.
Gilson CR; Zimring JC
Transfusion; 2012 Apr; 52(4):849-59. PubMed ID: 21981241
[TBL] [Abstract][Full Text] [Related]
36. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
Amemiya Y
Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
[TBL] [Abstract][Full Text] [Related]
37. Transfusion-induced bone marrow transplant rejection due to minor histocompatibility antigens.
Patel SR; Zimring JC
Transfus Med Rev; 2013 Oct; 27(4):241-8. PubMed ID: 24090731
[TBL] [Abstract][Full Text] [Related]
38. Human leucocyte antigen alloimmunization after bone marrow transplantation: an association with chronic myelogenous leukaemia.
Geiger TL; Woodard P; Tong X; Srivastava DK; Johnson R; Turner V; Hale G; Richardson S
Br J Haematol; 2002 Jun; 117(3):634-41. PubMed ID: 12028035
[TBL] [Abstract][Full Text] [Related]
39. Alloimmunogenicity of an isolated MHC allele is affected by the context of MHC mismatch in a murine model.
Hudson KE; Wong ASL; Richards AL; Kapp LM; Zimring JC
Transfusion; 2019 Feb; 59(2):744-753. PubMed ID: 30681727
[TBL] [Abstract][Full Text] [Related]
40. Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension.
Claas FH; Smeenk RJ; Schmidt R; van Steenbrugge GJ; Eernisse JG
Exp Hematol; 1981 Jan; 9(1):84-9. PubMed ID: 7238645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
